TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03002337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Description: All of the participants in the aromatherapy group underwent aromatherapy massage for 70 minutes every two weeks between 16 to 36 weeks GA (ten sessions total). The aromatic massage oils were composed of 2 c.c. lavender (Lavandula angustifolia) blended with 98 c.c. almond oil. This concentration of the mixed essential oil was kept at room temperature for massage use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga exercise
Description: Prenatal yoga was offered in six 70-minute yoga sessions per week for 20 weeks, with 10-12 women in each session. Each participant should attend two sessions of yoga every two days, held in a quiet room near the prenatal clinic. Yoga specifically designed for women during the second and third trimesters, was guided by a midwife who was certified as a yoga instructor. Yoga included physical postures/ stretch, deep breathing, guided imagery, and deep relaxation. Before each posture/stretch, the instructor guided participants to relax each body part and calm their mind.
Study: NCT02713464

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: maternal education
Description: Antenatal and/or postpartum Instruction on risks of neonatal jaundice, dangerous practices, technique to evaluate jaundice, early signs of ABE, when to seek care.
Study: NCT02592590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group A
Description: This condition receives three study components:~1. The base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, quiz questions), activity tracking, and graphical feedback.~2. The guided goal-setting module within the app that utilizes participant activity preferences and experiences, as well as performance within the program to guide the setting of high-quality short and long-term physical activity goals. These goals form the basis of the physical activity prescription.~3. The points-based feedback module. For each action in the app (e.g., setting goals, achieving goals, viewing weekly videos, answering quiz questions, tracking activity), a number of program points is awarded. These are weighted by task difficulty, and accumulate to earn levels. Levels accumulate to earn badges depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn titles (e.g., expert exerciser).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group B
Description: This condition receives two study components:~1. The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.~2. The second is the guided goal-setting module within the app that utilizes participant activity preferences and experiences, as well as performance within the program to guide the setting of high-quality short and long-term physical activity goals. These goals form the basis of the physical activity prescription.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group C
Description: This condition receives two study components:~1. The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.~2. The second is the points-based feedback module. For each action in the app (e.g., viewing weekly videos, answering quiz questions, tracking activity), a number of program points is awarded. These are weighted by task difficulty, and accumulate to earn levels. Levels accumulate to earn badges depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn titles (e.g., expert exerciser). As the intervention is goal drive, these participants will also receive printed goal setting worksheets.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group D
Description: This condition receives only the base-level smartphone app. This contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback. As the intervention is goal drive, these participants will also receive printed goal setting worksheets.
Study: NCT02538224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.5%ketoprofen gel + 3 % doxycycline
Description: GroupA:(0.05cc, mixed gel) be put into the periodontal pocket using an insulin syringe.~Intervention category Treatment: drugs

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: :2.5%ketoprofen gel
Description: GroupB:2.5%ketoprofen gel which be inserted into the periodontal pocket using an insulin syringe .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: :2.5%ketoprofen gel
Description: GroupB:2.5%ketoprofen gel which be inserted into the periodontal pocket using an insulin syringe .
Study: NCT00331097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 35 mg/m2 intravenously on days 1, 8, and 15 every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 600 mg/m2 intravenously days 1, 8 every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: 40 mg/m2 intravenously days 1 and 8 every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 600 mg/m2 intravenously days 1 and 8 every 28 days
Study: NCT02434406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet-What Am I Worried About
Description: This web-based intervention consists of three sections: 1) Is this for me? 2) Practice 3) Understanding. The three main sections are divided up into nine sessions. Participants will get access to the program for eight weeks and can access the sessions more than once. Sessions are made up of multimedia presentations and worksheets that are completed online.
Study: NCT01534702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine, cytarabine, idarubicin
Description: Treatment is stratified according to patients age (\< 60 years vs. ≥ 60 years).~Medication:~Patients \< 60 years:~* idarubicin 7.5 mg/m2 iv, days 1 + 3~* cytarabine 750 mg/m2 iv, days 1 to 5~Patients ≥ 60 years:~* idarubicine 6 mg/m2 iv, days 1 + 3~* cytarabine 750 mg/m2 iv, days 1 to 5~Clofarabine will be given in escalating doses to cohorts of at least three patients:~Clofarabine:~* level -1: 15 mg/m2 iv, days 1 to 5~* level 1: 20 mg/m2 iv, days 1 to 5~* level 2: 25 mg/m2 iv, days 1 to 5~* level 3: 30 mg/m2 iv, days 1 to 5~* level 4: 35 mg/m2 iv, days 1 to 5~Patients will be recruited according to a 3+3 design. New cohorts will be initiated depending on toxicity of the previous cohort during the first induction cycle. Enrollment will begin with dose level 1.
Study: NCT05488535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cochlear implant headpiece
Description: investigational cochlear implant headpiece
Study: NCT04558034

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: cryotherapy will be delivered
Study: NCT00914316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Ranolazine, 1000 mg, capsule, twice daily, by mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Ranolazine, 1000 mg, capsule, twice daily, by mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Ranolazine, 1000 mg, capsule, twice daily, by mouth.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: twice daily
Study: NCT02979496

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 0 g pomace (control)
Description: 16 oz of juice containing 0 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 90 g pomace
Description: 16 oz of juice containing 90 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 180 g pomace
Description: 16 oz of juice containing 180 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Flavored water (control)
Description: 16 oz of a flavored, calorie-matched water beverage will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
Study: NCT02352389

Intervention type: OTHER
Intervention: Blood sample
Description: Blood samples will be drawn and analyzed at Day 0, 7, 14, 21, and 28

Intervention type: OTHER
Intervention: Nasal swab
Description: Obtained on Day 0, 7, 14, 21 and 28.

Intervention type: OTHER
Intervention: Oropharyngeal swab
Description: Obtained on Day 0, 7, 14, 21 and 28.

Intervention type: OTHER
Intervention: Stool sample
Description: Obtained on Day 0, 7, 14, 21 and 28.

Intervention type: OTHER
Intervention: Symptom checklist
Description: Obtained on Day 0, 7, 14, 21 and 28.
Study: NCT00865566

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA plasmid vaccine
Description: 4-mg injection administered as 1 mL intramuscularly (IM) via Biojector® in either deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant adenoviral serotype 5 (rAD5) vector vaccine
Description: 1 x 10\^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DNA vaccine placebo
Description: 1 mL IM via Biojector® in either deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: HIV-1 recombinant adenovirus vaccine placebo
Description: 1 mL administered IM by needle and syringe in either deltoid
Study: NCT02395471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosponge™ Cell Collection Device
Description: Cytosponge™ Cell Collection Device is indicated for use in the collection and retrieval of surface cells in the esophagus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosponge™ Cell Collection Device
Description: Cytosponge™ Cell Collection Device is indicated for use in the collection and retrieval of surface cells in the esophagus.
Study: NCT02739061

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral group therapy
Description: Establish closed every collection of six or so patients structured group. Each group patients were treated for 12 times, once a week, 120 minutes at a time.~Treatment for 1 to 3 times to obsessive-compulsive disorder and cognitive behavioral therapy as the theme of psychological education; 4 to 6, 8 to 10 times exposed step by step and reaction treatment and prevention of training;7 and 11 times invite patients family members or other caregivers, make education about obsessive-compulsive disorder cognitive behavioural therapy, to promote patients exposed response prevention homework completion and social support; The 12th time treatment is self assessment and treatment guidelines for a long time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline, fluvoxamine
Description: Select specified drugs (sertraline, fluvoxamine)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral group therapy and drug therapy
Description: Select specified drugs (sertraline, fluvoxamine) and start group cognitive behavior therapy for 12 weeks at the same time
Study: NCT00604799

Intervention type: DEVICE
Group type: OTHER
Intervention: Talent Thoracic Stent Graft
Description: TEVAR

Intervention type: DEVICE
Group type: OTHER
Intervention: Talent Thoracic Stent Graft
Description: TEVAR

Intervention type: DEVICE
Group type: OTHER
Intervention: Talent Thoracic Stent Graft
Description: TEVAR

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Talent Thoracic Stent Graft
Description: TEVAR
Study: NCT00588835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: 125mg on Day 1; 80mg on Day 2-3 during CE cycle. Dexamethasone is added as well.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone and Ondansetron during CE-treatment
Description: Standard anti-emetic regimen during CE treatment
Study: NCT01887483

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vetal Laban active
Description: Dairy product with probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dairy product without probiotic
Study: NCT04204525

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative sensory testing
Description: Electrical detection and pain thresholds will be determined (at the sural nerve of the dominant leg and at the median nerve of both arms) with a constant current electrical stimulator.~Endogenous pain facilitation will be assessed by a temporal summation paradigm by delivering 20 electrical stimuli at the intensity of the electrical pain threshold.~Endogenous pain inhibition will be assessed by a conditioned pain modulation paradigm with electrical stimulation as test stimulus and the cold pressor test as conditioning stimulus.~EEG measurements with be performed with scalp EEG with 32 surface Sn electrodes in a headcap in referential montage following the standard 10-20 recording system.~A 5 minute resting state measurement will be performed with eyes closed, followed by EEG measurements during the condition pain modulation paradigm to assess the evoked-related potentials.

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative sensory testing
Description: Electrical detection and pain thresholds will be determined (at the sural nerve of the dominant leg and at the median nerve of both arms) with a constant current electrical stimulator.~Endogenous pain facilitation will be assessed by a temporal summation paradigm by delivering 20 electrical stimuli at the intensity of the electrical pain threshold.~Endogenous pain inhibition will be assessed by a conditioned pain modulation paradigm with electrical stimulation as test stimulus and the cold pressor test as conditioning stimulus.~EEG measurements with be performed with scalp EEG with 32 surface Sn electrodes in a headcap in referential montage following the standard 10-20 recording system.~A 5 minute resting state measurement will be performed with eyes closed, followed by EEG measurements during the condition pain modulation paradigm to assess the evoked-related potentials.
Study: NCT01241201

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Priobiotic supplement VSL#3
Description: four weeks, twice daily two sachets of VSL#3, a priobitics mixture
Study: NCT00970996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 250 mg/m\^2 by mouth on days 1, 2, and 3 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 100 mg/m\^2 given in a short intravenous infusion 1 hour after completion of Temozolomide and a 2nd dose of 70 mg/m\^2 given on day 5 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 20 mg/m\^2 intravenously on days 1, 2, 3, and 4 delivered immediately after Abraxane of each 21-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 9 MIU/m\^2 in a continuous intravenous infusion over 24 hours on days 1, 2, 3, and 4 (total of 96 hours) beginning after completion of Cisplatin of each 21-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b
Description: 5 MIU/m\^2 in subcutaneous injection on days 1, 2, 3, 4, and 5 of each 21-day cycle.
Study: NCT03584789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: A clinical decision support system designed to assist dentists in providing optimal pain management for patients without resorting to opioids when a non-opioid alternative would suffice. It provides pertinent clinical information to the dentist, including point-of-care access to the Prescription Drug Monitoring Program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: A clinical decision support system designed to assist dentists in providing optimal pain management for patients without resorting to opioids when a non-opioid alternative would suffice. It provides pertinent clinical information to the dentist, including point-of-care access to the Prescription Drug Monitoring Program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education
Description: Patient education regarding pain management before and after dental extraction, including information about the risks and benefits of various strategies.
Study: NCT00598676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biodegradable polymer Rapamycin-eluting stent
Description: due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: permanent polymer rapamycin-eluting stent (Cypher)
Description: due to randomization, rapamycin-eluting stent with permanent polymer will be implanted

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: permanent polymer everolimus-eluting stent (Xience, Promus)
Description: due to randomization, everolimus-eluting stent with permanent polymer will be implanted
Study: NCT00467116

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400mg/m2 initial dose week 1; followed by 250mg/m2/weekly starting week 2 with gemcitabine at fixed dose rate (10 mg/m2/min) + XRT. Cetuximab will start 1 week prior to all other treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Dose Level Gemcitabine dose Gemcitabine infusion~-1 150mg/m2 15 Minutes 0 200mg/m2 20 minutes~1. 300mg/m2 30 minutes~2. 400mg/m2 40 minutes

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 50.4 Gy, 28 fractions, 5.5 weeks (1.8 Gy/day). A cone down after 45 Gy will be performed to encompass gross disease with a margin of 1-1.5 cm.~The prescription point will be designated at the intersection of the multiple beams.~There are no planned interruptions \> 3 days.
Study: NCT00529867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether/lumefantrine tablets
Description: Artemether/lumefantrine tablets containing 20mg artemether and 120mg lumefantrine~Dosage: 5 - 14.9 kg: 1 tablet and 15 - 24.9 kg: 2 tablets~Administered at 0, 8, 24, 36, 48, and 60 hours on days 0, 1, and 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether/Lumefantrine suspension
Description: Artemether/lumefantrine suspension containing 15mg artemether and 90mg lumefantrine per 5ml suspension~Dosage: 5.0 - 7.4 kg = 7 ml, 7.5 - 9.9 kg = 10 ml, 10 - 12.4 kg = 14 ml, 12.5 - 14.9 kg = 17 ml, 15 - 17.4 kg = 20 ml, 17.5 - 19.9 kg = 24 ml, 20 - 22.4 kg = 27 ml and 22.5 - 24.9 kg = 30 ml~Administered once daily at 0, 24, and 48 hours on days 0, 1 and 2
Study: NCT04782583

Intervention type: OTHER
Intervention: Questionnaire
Description: questionnaire for the patients and the volontaire

Intervention type: OTHER
Intervention: Questionnaire
Description: questionnaire for the patients and the volontaire
Study: NCT04412629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib should be taken on an empty stomach (at least 1 hour before or 2 hours after eating) at the same time every day.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood for plasma biomarkers
Description: Baseline, cycle 1 day 8, cycle 1 day 15, and day 1 of every cycle thereafter

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue biopsy
Description: Baseline, before start of cycle 2, and time of progression
Study: NCT02215252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771 150 mg
Description: PF-05089771 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matched placebo for PF-05089771 150 mg and pregabalin 300 mg
Description: Matched placebo for PF-05089771 150 mg twice daily and pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Description: Pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771 150 mg + Pregabalin 300 mg
Description: PF-05089771 150 mg twice daily oral capsules with pregabalin 150 mg twice daily oral capsules. Treatment period = 4 weeks.
Study: NCT02481661

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: segmentectomy
Description: segmentectomy in Arm I and lobectomy in Arm II

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: segmentectomy
Description: segmentectomy in Arm I and lobectomy in Arm II
Study: NCT01356628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: PD-0332991, 125mg, 3 cycles
Study: NCT04264936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC and JS001
Description: Recombinant Humanized anti-HER2(Human epidermal growth factor receptor-2) Monoclonal Antibody-MMAE(Monomethyl Auristatin E) Conjugate For Injection and JS001 Injection
Study: NCT03335670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Pentixafor
Description: 68Ga Pentixafor is a radiolabeled cyclic pentapeptide with high affinity for CXCR4 receptor
Study: NCT03646552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THX-110
Description: Participants will receive THX-110 in the following regimen:~Dronabinol will be slowly titrated in the first 10 days of the study and PEA will be given in a constant dose of 800mg per day for the entire duration of the study.~Patients will be followed for a total of 30 days.